292 related articles for article (PubMed ID: 28263668)
1. Monocytes, Macrophages, and Osteoclasts in Osteosarcoma.
Kelleher FC; O'Sullivan H
J Adolesc Young Adult Oncol; 2017 Sep; 6(3):396-405. PubMed ID: 28263668
[TBL] [Abstract][Full Text] [Related]
2. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.
Nardin A; Lefebvre ML; Labroquère K; Faure O; Abastado JP
Curr Cancer Drug Targets; 2006 Mar; 6(2):123-33. PubMed ID: 16529542
[TBL] [Abstract][Full Text] [Related]
3. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.
Pahl JH; Kwappenberg KM; Varypataki EM; Santos SJ; Kuijjer ML; Mohamed S; Wijnen JT; van Tol MJ; Cleton-Jansen AM; Egeler RM; Jiskoot W; Lankester AC; Schilham MW
J Exp Clin Cancer Res; 2014 Mar; 33(1):27. PubMed ID: 24612598
[TBL] [Abstract][Full Text] [Related]
4. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
Meyers PA; Chou AJ
Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182
[TBL] [Abstract][Full Text] [Related]
5. Mifamurtide for the treatment of nonmetastatic osteosarcoma.
Ando K; Mori K; Corradini N; Redini F; Heymann D
Expert Opin Pharmacother; 2011 Feb; 12(2):285-92. PubMed ID: 21226638
[TBL] [Abstract][Full Text] [Related]
6. Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma.
Meyers PA
Adv Exp Med Biol; 2020; 1257():133-139. PubMed ID: 32483736
[TBL] [Abstract][Full Text] [Related]
7. [L-MTP-PE--a potential antineoplastic agent].
Dzierzbicka K; Gozdowska M; Kołodziejczyk AM
Postepy Hig Med Dosw; 1997; 51(2):227-36. PubMed ID: 9235567
[TBL] [Abstract][Full Text] [Related]
8. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
9. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.
MacEwen EG; Kurzman ID; Helfand S; Vail D; London C; Kisseberth W; Rosenthal RC; Fox LE; Keller ET; Obradovich J
J Drug Target; 1994; 2(5):391-6. PubMed ID: 7704483
[TBL] [Abstract][Full Text] [Related]
10. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.
Anderson P
Future Oncol; 2006 Jun; 2(3):333-43. PubMed ID: 16787112
[TBL] [Abstract][Full Text] [Related]
11. The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis.
Endo-Munoz L; Evdokiou A; Saunders NA
Biochim Biophys Acta; 2012 Dec; 1826(2):434-42. PubMed ID: 22846337
[TBL] [Abstract][Full Text] [Related]
12. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.
Mori K; Ando K; Heymann D
Expert Rev Anticancer Ther; 2008 Feb; 8(2):151-9. PubMed ID: 18279055
[TBL] [Abstract][Full Text] [Related]
13. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma.
Kleinerman ES; Snyder JS; Jaffe N
J Clin Oncol; 1991 Feb; 9(2):259-67. PubMed ID: 1988574
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
[TBL] [Abstract][Full Text] [Related]
15. Drugs in early clinical development for the treatment of osteosarcoma.
Heymann MF; Brown HK; Heymann D
Expert Opin Investig Drugs; 2016 Nov; 25(11):1265-1280. PubMed ID: 27633385
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents.
Buddingh EP; Kuijjer ML; Duim RA; Bürger H; Agelopoulos K; Myklebost O; Serra M; Mertens F; Hogendoorn PC; Lankester AC; Cleton-Jansen AM
Clin Cancer Res; 2011 Apr; 17(8):2110-9. PubMed ID: 21372215
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.
Kurzman ID; Shi F; Vail DM; MacEwen EG
Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295
[TBL] [Abstract][Full Text] [Related]
18. Mifamurtide in osteosarcoma--a practical review.
Anderson PM; Tomaras M; McConnell K
Drugs Today (Barc); 2010 May; 46(5):327-37. PubMed ID: 20517534
[TBL] [Abstract][Full Text] [Related]
19. Patrolling monocytes inhibit osteosarcoma metastasis to the lung.
Chen T; Zhao L
Aging (Albany NY); 2020 Nov; 12(22):23004-23016. PubMed ID: 33203789
[TBL] [Abstract][Full Text] [Related]
20. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
Wojcik J; Rosenberg AE; Bredella MA; Choy E; Hornicek FJ; Nielsen GP; Deshpande V
Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
